Skip to content

Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness

Examining the Role of Protease-activated Receptor 2 Agonists in Gastrointestinal Dysfunction in Pediatric Surgical Critical Illness

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03011151
Enrollment
99
Registered
2017-01-05
Start date
2017-08-01
Completion date
2024-06-30
Last updated
2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Gastrointestinal Disorder, Functional, Gastroparesis

Keywords

pediatric, critical illness, surgery, gastrointestinal dysfunction, gastric emptying, epithelial barrier, nutrition

Brief summary

Gastrointestinal (GI) dysfunction affects up to 50% of medical and surgical critically ill children. GI dysfunction, specifically gastric dysmotility and loss of epithelial barrier integrity, is associated with significant morbidity in critical illness. The mechanisms underlying GI dysfunction in critical illness are not well understood. GI dysfunction in surgery and critical illness has been associated with inflammation. There is evidence to suggest the protease-activated receptor 2 (PAR2) is a link between inflammation and GI dysfunction. PAR2 is a G-coupled receptor present throughout the GI tract. PAR2 mediates GI motility and epithelial barrier integrity. PAR2 is activated by PAR2 agonists, specifically GI serine proteases and zonulin, released under conditions of inflammation. In this study the investigators will examine the relationship between inflammation and PAR2 activation by PAR2 agonists and subsequent GI dysfunction in pediatric critically ill surgical patients. The overall hypothesis of this study is that PAR2 activation by PAR2 agonists, GI serine proteases and zonulin, released due to inflammation results in gastric dysmotility and loss of epithelial barrier integrity. In this study, the investigators will examine whether PAR2 agonist expression is increased and correlates with GI dysfunction in critically ill surgical pediatric patients. This proposal fills a knowledge gap in the understanding of mechanisms for GI dysfunction in critical illness, and will be applicable to all surgical and medical critically ill children.

Detailed description

The investigators in this study aim to examine a plausible mechanism by which gastrointestinal dysfunction, gastric dysmotility and loss of epithelial barrier integrity, occur in critical illness. Specifically, the investigators will examine whether an increase in PAR2 agonist levels, zonulin and serine proteases, are associated with gastric dysmotility and loss of epithelial barrier integrity in critical surgical illness in children. The investigators will examine GI function, gastric motility and epithelial barrier integrity, and PAR2 agonist levels, zonulin and serine protease, in participants before surgery and after surgery. Specifically, children undergoing posterior spinal fusion, a known significant inflammatory trigger, and with planned admissions to the intensive care unit will be enrolled. Gastrointestinal function and PAR2 agonist levels will be tested non-invasively in blood and stool.

Interventions

None listed

Sponsors

Boston Children's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* 2 years and older

Exclusion criteria

* Liver dysfunction * Renal dysfunction * Pre-diagnosed gastroparesis/ delayed gastric emptying * Pre-diagnosed gastrointestinal malabsorption * Contraindication to acetaminophen administration

Design outcomes

Primary

MeasureTime frameDescription
PAR2 agonist activity- serum zonulinImmediately pre-operative versus post-operative day 1PAR2 agonist activity will be measured by serum zonulin levels (ng/mL)
PAR2 agonist activity- fecal protease activityImmediately pre-operative versus post-operative day 1PAR2 agonist activity will be measured by fecal serine protease activity (trypsin units/gm protein)

Secondary

MeasureTime frameDescription
Gastric motility by the acetaminophen absorption test- AUCImmediately pre-operative versus post-operative day 1Pharmacokinetic parameters of acetaminophen will be used to determined gastric motility including the concentration of acetaminophen at 60 minutes (mcg/mL).
Epithelial barrier integrity by serum biomarkersImmediately pre-operative versus post-operative day 1Epithelial barrier integrity by serum biomarkers, specifically serum zonulin (ng/mL) and lipopolysaccharide binding protein levels (ng/mL).

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOREnid Martinez, MD

Boston Children's Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026